ANIP Q2 2021 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$49M+0.3% YoY

Gross Profit

$26M54.1% margin

Operating Income

-$16M-32.0% margin

Net Income

-$14M-29.0% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

-10.8%

Cash Flow

Operating Cash Flow

$241,000

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$480M

Total Liabilities

$288M

Stockholders' Equity

$192M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$48M	+0.3%
Gross Profit	$26M	$28M	-5.3%
Operating Income	-$16M	-$11M	-37.6%
Net Income	-$14M	-$12M	-14.3%

Revenue Segments

Sales Of Generic Pharmaceutical Products

$34M69%

Sales Of Branded Pharmaceutical Products

$11M22%

Sales Of Contract Manufactured Products

$4M7%

Other Revenues

$969,0002%

Product Development Services

$97,0000%

Geographic Segments

U

$48M98%

C

$1M2%